Laden…
4-chloro-N-(2-morpholin-4-ylethyl)benzamide
Moclobemide is a reversible selective inhibitor of monoamine oxidase A (MAO-A), primarily used for the treatment of depression. It increases the concentration of monoamines such as serotonin, norepinephrine, and dopamine in the synaptic cleft without causing irreversible enzyme inhibition. Due to its reversible action, the risk of severe adverse effects and interactions is lower than with classical irreversible MAO inhibitors. However, interactions with certain foods and medications are possible, so caution is advised.
Receptor Targets
Mechanism of Action
Moclobemide acts through the following pharmacological mechanisms:
Designations
IUPAC: 4-chloro-N-(2-morpholinoethyl)benzamide
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Receptor Profile
Der 5-HT2A-Rezeptor ist ein Serotonin-Rezeptor der Klasse Gq-gekoppelter GPCRs. Er ist der primäre molekulare Angriffspunkt klassischer Psychedelika und spielt eine Rolle bei Kognition und Wahrnehmung.
Der 5-HT1A-Rezeptor ist ein Gi/Go-gekoppelter Serotoninrezeptor, der als Autorezeptor auf serotonergen Neuronen und als Heterorezeptor in verschiedenen Hirnregionen vorkommt. Er moduliert Angst, Stimmung und Kognition.
Der Noradrenalintransporter (NET) ist ein Monoamintransporter, der Noradrenalin aus dem synaptischen Spalt zurücktransportiert. Er wird von verschiedenen Stimulanzien und Antidepressiva beeinflusst.
Der Dopamintransporter (DAT) ist ein Natrium-abhängiger Monoamintransporter, der Dopamin aus dem synaptischen Spalt entfernt. Er ist ein zentrales Ziel von Stimulanzien und spielt eine Schlüsselrolle im Belohnungssystem.
Monoaminoxidase A (MAO-A) ist ein mitochondriales Enzym, das Serotonin, Noradrenalin und Dopamin oxidativ desaminiert. Hemmung führt zu erhöhten Monoamin-Spiegeln und ist die Grundlage der MAO-Hemmer-Therapie bei Depression.
Synapedia Evidence
Effects & Pharmacology is partially translated. Some content may appear in German.
Total duration 24 hours
Peak
4-6 weeks
Onset
1-2 weeks
Total duration
24 hours
After effects
unknown
Start low. Individual sensitivity varies.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Moclobemid kann Wechselwirkungen mit anderen Medikamenten haben und sollte mit Vorsicht angewendet werden.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.